Healthtech Solutions (HLTT) 10-K 2 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 02, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity File Number	0-51012
Entity Registrant Name	Healthtech Solutions, Inc./UT
Entity Central Index Key	0001307624
Entity Tax Identification Number	84-2528660
Entity Incorporation, State or Country Code	UT
Entity Address, Address Line One	90 Broad Street, 16th Floor,
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Country	US
Entity Address, Postal Zip Code	10004
City Area Code	844
Local Phone Number	926-3399
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 323,583
Entity Common Stock, Shares Outstanding		9,701,269

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 128,996
Prepaid expenses	10,000
Due From related party		105,754
Total Current Assets	138,996	105,754
Intangible assets net of accumulated amortization	25,926	64,815
Total Assets	164,922	170,569
Current Liabilities:
Accrued interest	3,792
Accounts payable	80,169	36,400
Total Current Liabilities	83,961	36,400
Long Term Liabilities:
Convertible debentures payable, net of discount of $325,824	305,684
Derivative liabilities	337,874
Total Long Term Liabilities	643,558
Total  Liabilities	727,519	36,400
Stockholders' Equity (Deficit):
Series A preferred stock, $.001 par value, 2,000,000 authorized, 156,837 issued and outstanding	157
Common Stock, $0.001 par value, 200,000,000 shares authorized, 9,701,269 issued and outstanding	9,701
Additional paid-in capital	866,251	840,667
Accumulated deficit	(1,438,706)	(706,498)
Total Stockholders' Equity (Deficit)	(562,597)	134,169
Total Liabilities and Stockholders' Equity (Deficit)	164,922	$ 170,569
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit):
Series A preferred stock, $.001 par value, 2,000,000 authorized, 156,837 issued and outstanding	157
Total Stockholders' Equity (Deficit)	157
Total Liabilities and Stockholders' Equity (Deficit)	$ 157

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Series A Preferred Stock,shares authorized	2,000,000	2,000,000
Series A Preferred Stock, par value per share	$ 0.001	$ 0.001
Series A Preferred Stock, shares issued	156,837	156,837
Series A Preferred Stock,shares outstanding	156,837	156,837
Common stock, shares authorized	200,000,000	200,000,000
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares issued	9,701,269	9,701,269
Common stock, shares outstanding	9,701,269	9,701,269
Convertible debentures payable, net of discount	$ 325,824
Series A Preferred Stock [Member]
Series A Preferred Stock,shares authorized	2,000,000
Series A Preferred Stock, par value per share	$ 0.001
Series A Preferred Stock, shares issued	156,837
Series A Preferred Stock,shares outstanding	156,837

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue
Operating Expenses:
General & administrative	115,403	71,101
General and administrative-related party	129,733	119,137
Research and development	348,773	206,441
Research and development – related party	77,060	113,100
Amortization	38,889	38,889
Total Operating Expenses	709,858	548,668
Loss from Operations	(709,858)	(548,668)
Other Expenses:
Interest Expense	(19,577)
Change in fair value of derivative liabilities	(2,773)
Total Other Expenses	(22,350)
Net loss Before Provision for Income Tax	(732,208)	(548,668)
Provision for income tax	0
Net Loss	$ (732,208)	$ (548,668)
Loss per common share, Basic and diluted	$ (0.61)
Weighted average shares outstanding, Basic and diluted	1,198,321

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' (Deficiency) Equity - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Total
Balance, shares at Dec. 31, 2018		156,837
Balance, value at Dec. 31, 2018		$ 157	$ 466,510	$ (157,830)	$ 308,837
Capital contributions			374,000		374,000
Effect of reverse merger transaction, value
Net Loss				(548,668)	(548,668)
Balance, shares at Dec. 31, 2019		156,837
Balance, value at Dec. 31, 2019		$ 157	840,510	(706,498)	134,169
Capital contributions			270,442		270,442
Effect of reverse merger transaction, shares	9,701,269
Effect of reverse merger transaction, value	$ 9,701		(244,701)		(235,000)
Net Loss				(732,208)	(732,208)
Balance, shares at Dec. 31, 2020		156,837
Balance, value at Dec. 31, 2020		$ 157	$ 866,251	$ (1,438,706)	$ (562,597)

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (732,208)	$ (548,668)
Adjustments to Reconcile Net Loss to Net Cash used in operating activities
Amortization expense	38,889	38,889
Interest expense capitalized to convertible debentures payable	6,508
Amortization of discount on convertible debentures	9,277
Fair value change in derivative liabilities	2,773
Changes in operating assets and liabilities:
Prepaid expenses	10,000
Due From related party	(105,754)	(115,375)
Accrued interest	3,792
Accounts payable	43,769	20,404
Net cash used in operating activities	(531,446)	(374,000)
Cash flows from investing activities:
Cash paid upon reverse merger	235,000
Net cash used in investing activities	(235,000)
Cash flows from financing activities:
Proceeds from convertible debentures	625,000
Capital contributions	270,442	374,000
Net cash provided by financing activities	895,442	374,000
Net change in cash, cash equivalents, and restricted cash	128,996
Cash, cash equivalents, and restricted cash beginning of year
Cash, cash equivalents, and restricted cash end of year	128,996
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for taxes

Organization And Nature Of Busi

Organization And Nature Of Business	12 Months Ended
	Dec. 31, 2020
Organization And Nature Of Business
Organization and Nature of Business	NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Healthtech Solutions, Inc. (the “Company”) was incorporated in Utah on October 18, 1985. The Company had no business operations from April 25, 2015, when it spun off its only direct subsidiary, which at that time owned all of the assets through which the Company was carrying on operations, until November 16, 2020 when the Company acquired all of the outstanding capital stock of Medi-Scan Inc. Medi-Scan Inc. was organized as a limited liability company named "Medi-Scan LLC" formed in the State of Florida on September 25, 2018. On August 25, 2020, Medi-Scan LLC filed articles of conversion with the State of Florida that converted it from an LLC to a corporation. In connection with the conversion Medi-Scan Inc. issued 10,000 shares of common stock in exchange for the outstanding membership interest of Medi-Scan LLC. In December 2018, Medi-Scan acquired a portfolio of intellectual property relating to medical imaging. Richard F. Parker assigned his intellectual property to Medi-Scan and joined Medi-Scan as its Chief Research Officer. Since December 2018, Medi-Scan has been engaged in developing practical applications for the medical imaging technology as well as related medical technology. Recently Medi-Scan applied for three patents based on the technology developed in the past two years. Acquisition of Medi-Scan Inc. On November 12, 2020, Healthtech Solutions, Inc. entered into an exchange agreement with Medi-Scan, Inc. ("Medi-Scan") and all of the shareholders of Medi-Scan, pursuant to which the shareholders of Medi-Scan agreed to transfer all of the issued and outstanding stock of Medi-Scan to Healthtech Solutions, Inc., and Healthtech Solutions, Inc. agreed to issue to the shareholders of Medi-Scan, Inc. 156,837 shares of its Series A Preferred Stock, representing 97% of the equity in Healthtech Solutions. The exchange of equity (the "Share Exchange") was completed on November 16, 2020. As a result of the Share Exchange, the Medi-Scan shareholders become the majority shareholders and have control of Healthtech Solutions. The acquisition of Medi-Scan was accounted for as a reverse merger effected by a Share Exchange. Healthtech Solutions is considered the legal acquirer and Medi-Scan is considered the accounting acquirer. Accordingly, the historical financial statements presented in this report are those of Medi-Scan. On November 12, 2020, when the Share Exchange Agreement was executed, the three members of the Healthtech Solutions Board of Directors were also the three managing members of Medi-Scan, entities under their control owned a majority of the outstanding capital stock of Medi-Scan, and an entity under the control of one of them owned a majority of the outstanding capital stock of Healthtech Solutions. Therefore, the Share Exchange was accounted for as a business combination of entities under common control in accordance with ASC 805-50-30-5. Accordingly, the assets and liabilities of Medi-Scan are presented at their carrying values at the date of the Share Exchange, and the Company’s historical stockholders’ equity has been retroactively restated to the first period presented.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Summary Of Significant Accounting Policies
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Consolidation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Medi-Scan Inc. All significant inter-company accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements. Management makes these estimates using the best information available at the time the estimates are made; however, actual results could differ from those estimates. One significant item subject to such estimates and assumptions is the valuation of the derivative liabilities. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates. Concentrations of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash. Software Development Costs In accordance with ASC 985-20, the Company expenses software development costs, including costs to develop software products or the software component of products to be sold, leased, or marketed to external users, before technological feasibility is reached. Technological feasibility is typically reached shortly before the release of such products. Software development costs also include costs to develop software to be used solely to meet internal needs and cloud-based applications used to deliver our services. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed, and the software will be used to perform the function intended. Capitalization ends, and amortization begins when the product is available for general release to customers. Research and Development Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses. Impairment of Intangible Assets The Company reviews intangible assets for impairment when events or changes in circumstances indicate the carrying amount may not be recoverable. The Company measures recoverability of these assets by comparing the carrying amounts to the future undiscounted cash flows that the assets or the asset group are expected to generate. If the carrying value of the assets are not recoverable, the impairment recognized is measured as the amount by which the carrying value of the asset exceeds its fair value. Management has determined that no impairment exists as of December 31, 2020. Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. Convertible Instruments (Continued) See Derivative Financial Instruments Share-Based Compensation The Company follows the provisions of FASB ASC 718 requiring employee equity awards to be accounted for under the fair value method. Accordingly, share-based compensation is measured at grant date, based on the fair value of the award and recognized over its vesting period. No equity instruments were granted during the year ended December 31, 2020 and no compensation expense is required to be recognized under provisions of ASC 718 with respect to employees. Fair Value of Financial Instruments The Company follows ASC 825-10-50-10 with respect to disclosures about fair value of its financial instruments and ASC 820-10-35-37 to measure the fair value of its financial instruments. ASC 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: · Level 1: Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. · Level 2: Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. · Level 3: Pricing inputs that are generally unobservable inputs and not corroborated by market data. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. Financial assets and liabilities of the Company primarily consists of cash, prepaid expenses, accounts payable and accrued liabilities, other payables and convertible debentures. As at December 31, 2020 and 2019, the carrying values of these financial instruments (other than convertible debentures) approximated their fair values due to the short-term nature of these instruments. Fair Value of Financial Instruments (Continued) See: The derivative liability, which relates to the conversion feature of convertible debt, is classified as a Level 3 liability, and is the only financial liability measure at fair value on a recurring basis. There were no transfers between level 1, level 2 or level 3 measurements during the years ended December 31, 2020 and 2019. Earnings Per Share The Company calculates earnings per share (“EPS”) as required by ASC 260, Earnings Per Share Income Taxes The Company follows ASC Topic 740, Income Taxes ASC 740-10-30 requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under ASC 740-10-30, tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Under ASC 740-10-40, previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met. The Company had no material uncertain tax positions as of December 31, 2020 or 2019. Income Taxes (Continued) The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or the deferred tax asset valuation allowance. Recently Adopted Accounting Standards The Company has reviewed other recently issued accounting pronouncements and plans to adopt those that are applicable to it. The Company does not expect the adoption of any other pronouncements to have an impact on its results of operations or financial position.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2020
Going Concern
Going Concern	NOTE 3 – GOING CONCERN The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not completed its efforts to establish a source of revenues sufficient to cover its operating costs over an extended period of time and has an accumulated deficit of $ 1,438,706 In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to most other countries and infections have been reported globally. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but it may have a material adverse impact on our business, financial condition and results of operations. Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time. Management anticipates that the Company will be dependent, for the near future, on additional investment capital or debt to fund operating expenses until its planned operations begin to generate revenue. The Company is not expecting to recognize revenue until the second half of 2021 at the earliest. Management, therefore, is actively pursuing sources of investment capital. However, no commitment of capital has been obtained at this time.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2020
Intangible Assets
Intangible Assets	NOTE 4 – INTANGIBLE ASSETS The Company’s intangible assets consist of the intellectual property relating to medical imaging contributed to Medi-Scan in December 2018 as a capital contribution. The intangible assets are being amortized over three years. Amortization expense relating to the intangible assets aggregated $38,889 in each of the years ending December 31, 2020 and 2019.

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2020
Related Parties
Related Parties	NOTE 5 – RELATED PARTIES During 2019 and the the first five months of 2020, Medi-Scan paid $10,000 per month to a law firm owned by Denis Kleinfeld, who was a managing member of Medi-Scan at that time and became a member of the Board of Directors of Healthtech Solutions in September 2020. The payment included $1,447 as compensation for use of the law firm's offices as the executive offices of Medi-Scan, the remainder was compensation for the administrative and other services of employees of the law firm, and for legal services by Mr. Kleinfeld. For legal services rendered as counsel to Healthtech Solutions during 2019 and 2020, Healthtech Solutions paid Robert Brantl $51,228. Mr. Brantl was the sole officer and director of Healthtech Solutions until September 4, 2020, and has served as Secretary of Healthtech Solutions since September 4, 2020. The initial capital contributions to Medi-Scan were held in an account in the name of a company owned by one of the managing members of Medi-Scan. The expenses of Medi-Scan were paid from this account. This practice was terminated during the first half of 2020. As of December 31, 2019 and 2020, the amount remaining in the account was $105,754 and $0, respectively. These amounts have been presented as due from related party on the accompanying balance sheets. In May 2020 David Rubin, through his personal holding company, Storm Funding LLC, agreed to contribute $250,000 to Medi-Scan in exchange for a 25% equity interest in Medi-Scan. During the remainder of 2020, Mr. Rubin satisfied $245,442 of the obligation: he contributed $142,761 by paying obligations incurred by Medi-Scan in that amount, and Mr. Rubin satisfied a total of $102,681 of the obligation by contributing to Medi-Scan the services of administrative employees employed by eProdigy Financial LLC, a company owned by Mr. Rubin. The hourly market value of services performed by eProdigy employees for the benefit of Medi-Scan was credited to Mr. Rubin's capital account.

Shareholders Equity

Shareholders Equity	12 Months Ended
	Dec. 31, 2020
Shareholders Equity
Shareholders Equity	NOTE 6 – SHAREHOLDERS EQUITY Authorized Capital Stock The following table sets forth information, as of the filing date of this Report, regarding the classes of capital stock that are authorized by the Articles of Incorporation of Healthtech Solutions, Inc. Class Shares Authorized Shares Outstanding Common Stock, $.001 par value 200,000,000 9,701,269 Series A Preferred Stock, $.001 par value 156,937 156,837 Undesignated Preferred Stock, $.001 par value 1,843,163 0 Series A Preferred Stock Undesignated Preferred Stock Capital Contributions Medi-Scan's founders contributed $25,000 during the year ended December 31, 2020, $374,000 during the year ending December 31, 2019 and $350,000 during the period ending December 31, 2018. In December 2018, the Richard F. Parker and Charlotte Parker Revocable Living Trust acquired a 25% membership interest in Medi-Scan in consideration of Richard F. Parker's contribution of intellectual property to Medi-Scan. The contribution was valued at $116,667, which was based on the capital contributions by the founding members of the Company. On May 21, 2020, Medi-Scan entered into agreement with Storm Funding LLC, a company owned by David Rubin. Storm Funding LLC committed to invest $250,000 in exchange for a 25% membership interest in Medi-Scan. At the same time, David Rubin joined Medi-Scan as Executive Chairman. As of December 31, 2020, $245,442 of the commitment had been invested into Medi-Scan.

Exchangeable Notes And Converti

Exchangeable Notes And Convertible Debentures	12 Months Ended
	Dec. 31, 2020
Exchangeable Notes And Convertible Debentures
Exchangeable Notes and Convertible Debentures	NOTE 7 – EXCHANGEABLE NOTES AND CONVERTIBLE DEBENTURES In August and September of 2020, Medi-Scan issued four 7% Exchangeable Promissory Notes in the aggregate principal amount of $375,000. Principal and interest were payable on the Notes on January 31, 2021. The Notes provided that, in the event that Medi-Scan was acquired by a corporation whose common stock was registered with the SEC, the Notes would be automatically exchanged for 7% convertible debentures issued by that acquirer. In November of 2020, by reason of the Share Exchange, the four 7% Exchangeable Promissory Notes were automatically exchanged for 7% Convertible Debentures issued by Healthtech Solutions in a principal amount of $381,505, which was equal to the principal of and accrued interest on the Notes. Then, during December of 2020, Healthtech Solutions issued four additional 7% Convertible Debentures in the aggregate principal amount of $250,000 in exchange for payment of cash in that amount. The 7% Convertible Debentures are convertible into common stock, at the holders’ option, at a 30% discount to the market price of the Company’s common stock. The Company has determined that the conversion feature represents a derivative financial instrument embedded in the Debentures. The accounting treatment of derivative financial instruments requires that the Company record the fair value of that derivative financial instrument as a discount to the value of the Debentures as of the inception date of each Debenture. Accordingly, the Company recorded an aggregate initial discount of $335,101 for the fair value of the derivative liability at inception of each convertible debenture. During the year ended December 31, 2020, the Company amortized $9,277 as interest expense. At December 31, 2020 the notes are presented on the balance sheet net of unamortized discount of $325,824.

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Dec. 31, 2020
Derivative Financial Instruments
Derivative Financial Instruments	NOTE 8 – DERIVATIVE FINANCIAL INSTRUMENTS The Company determined the conversion feature of the 7% Convertible Debentures, which all contain variable conversion rates, represented an embedded derivative since the Debentures were convertible into a variable number of shares upon conversion. Accordingly, the Debentures are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated from the debt host and accounted for as a derivative liability. The fair value of the derivatives embedded in the 7% Convertible Debentures was determined using Monte Carlo simulation method based on the following assumptions: (1) dividend yield of 0%, (2) expected volatility of 167%, (3) weighted average risk-free interest rate of 9.0%, (4) expected life until January 31, 2024, and (5) the quoted market price of the Company’s common stock at each valuation date. At December 31, 2020, the Company marked to market the fair value of the eight derivatives and determined a fair value of $337,874. The Company recorded a loss resulting from change in fair value of debt derivatives by $2,773 for the year ended December 31, 2020. A summary of changes in Convertible Debentures for the period ended December 31, 2020 was as follows: Balance at January 1, 2020 -- Issued during the year $ 335,101 Change in fair value recognized in operations $ 2,773 Balance at December 31, 2020 $ 305,684 At December 31, 2019, the Company had no derivative financial instruments outstanding.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Taxes
Income Taxes	NOTE 9 – INCOME TAX As discussed in Note 1, in prior years and through August 25, 2020, the Company was a limited liability company which was treated as a partnership for income tax purposes, and the tax benefit of losses realized by the Company was passed on to its members. The provision (benefit) for income taxes consisted of the following for the period from conversion to December 31, 2020: 2020 Current $ 0 Deferred (111,000 ) Change in valuation allowance 111,000 Income tax provision (benefit) $ 0 The following table reconciles the effective income tax rates with the statutory rates for the period from the conversion date to December 31, 2020: U.S. federal statutory rate 21.0 % State tax, net of federal benefit 5.0 % Change in valuation allowance 26.0 % Effective income tax rate — % Deferred tax assets are comprised of the following: December 31, 2020 Net operating loss carryforwards $ 111,000 Valuation allowance (111,000 ) Net deferred tax assets $ 0 At December 31, 2020, the Company had approximately $427,000 of federal net operating losses that may be available to offset future taxable income. The Federal net operating loss carryover, if not utilized, will expire beginning in 2027. Through 2036, the amount and utilization of any future net operating loss carry-forwards may be subject to limitations set forth by the Internal Revenue Code. Based upon an analysis of the Company’s stock ownership activity through December 31, 2020, a change of ownership was deemed to have occurred in the 2020 fiscal year. This change of ownership created an annual limitation of substantially all of the Company’s net operating losses which are available through 2036. The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s losses since inception, management believes that it is more likely than not that future benefit of the deferred tax asset will not be realized principally due to the continuing losses from operations and the change of ownership limitations and has therefore established a full valuation allowance. The valuation allowance was increased by $111,000 during the year ended December 31, 2020. The tax years ended December 31, 2020 and June 30, 2020, 2019 and 2018 remain open to examination by the taxing authorities.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2020
Contingencies
Contingencies	NOTE 10 – CONTINGENCIES Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed. The Company was not subject to any material loss contingencies as of December 31, 2020 or 2019 and through the date of this report.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events
Subsequent Events	NOTE 11 – SUBSEQUENT EVENTS In accordance with ASC 855-10, the Company’s management has performed subsequent events procedures through the date these financial statements were issued. No subsequent events required adjustment to or disclosure in the financial statements.

Summary Of Significant Accoun_2

Summary Of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Disclosure Accounting Policies Policies Abstract
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Medi-Scan Inc. All significant inter-company accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements. Management makes these estimates using the best information available at the time the estimates are made; however, actual results could differ from those estimates. One significant item subject to such estimates and assumptions is the valuation of the derivative liabilities. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.
Concentrations of Credit Risk	Concentrations of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash.
Software Development Costs	Software Development Costs In accordance with ASC 985-20, the Company expenses software development costs, including costs to develop software products or the software component of products to be sold, leased, or marketed to external users, before technological feasibility is reached. Technological feasibility is typically reached shortly before the release of such products. Software development costs also include costs to develop software to be used solely to meet internal needs and cloud-based applications used to deliver our services. The Company capitalizes development costs related to these software applications once the preliminary project stage is complete and it is probable that the project will be completed, and the software will be used to perform the function intended. Capitalization ends, and amortization begins when the product is available for general release to customers.
Research and Development	Research and Development Research and development costs are expensed when incurred. Research and development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical trial expenses.
Impairment of Intangible Assets	Impairment of Intangible Assets The Company reviews intangible assets for impairment when events or changes in circumstances indicate the carrying amount may not be recoverable. The Company measures recoverability of these assets by comparing the carrying amounts to the future undiscounted cash flows that the assets or the asset group are expected to generate. If the carrying value of the assets are not recoverable, the impairment recognized is measured as the amount by which the carrying value of the asset exceeds its fair value. Management has determined that no impairment exists as of December 31, 2020.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. See Derivative Financial Instruments
Share-Based Compensation	Share-Based Compensation The Company follows the provisions of FASB ASC 718 requiring employee equity awards to be accounted for under the fair value method. Accordingly, share-based compensation is measured at grant date, based on the fair value of the award and recognized over its vesting period. No equity instruments were granted during the year ended December 31, 2020 and no compensation expense is required to be recognized under provisions of ASC 718 with respect to employees.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company follows ASC 825-10-50-10 with respect to disclosures about fair value of its financial instruments and ASC 820-10-35-37 to measure the fair value of its financial instruments. ASC 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: · Level 1: Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. · Level 2: Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. · Level 3: Pricing inputs that are generally unobservable inputs and not corroborated by market data. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. Financial assets and liabilities of the Company primarily consists of cash, prepaid expenses, accounts payable and accrued liabilities, other payables and convertible debentures. As at December 31, 2020 and 2019, the carrying values of these financial instruments (other than convertible debentures) approximated their fair values due to the short-term nature of these instruments. Fair Value of Financial Instruments (Continued) See: The derivative liability, which relates to the conversion feature of convertible debt, is classified as a Level 3 liability, and is the only financial liability measure at fair value on a recurring basis. There were no transfers between level 1, level 2 or level 3 measurements during the years ended December 31, 2020 and 2019.
Earnings Per Share	Earnings Per Share The Company calculates earnings per share (“EPS”) as required by ASC 260, Earnings Per Share
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes ASC 740-10-30 requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Under ASC 740-10-30, tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Under ASC 740-10-40, previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met. The Company had no material uncertain tax positions as of December 31, 2020 or 2019. The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or the deferred tax asset valuation allowance.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards The Company has reviewed other recently issued accounting pronouncements and plans to adopt those that are applicable to it. The Company does not expect the adoption of any other pronouncements to have an impact on its results of operations or financial position.

Shareholders Equity (Tables)

Shareholders Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Shareholders Equity Tables Abstract
Summary of Shareholders Equity	The following table sets forth information, as of the filing date of this Report, regarding the classes of capital stock that are authorized by the Articles of Incorporation of Healthtech Solutions, Inc. Class Shares Authorized Shares Outstanding Common Stock, $.001 par value 200,000,000 9,701,269 Series A Preferred Stock, $.001 par value 156,937 156,837 Undesignated Preferred Stock, $.001 par value 1,843,163 0

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Derivative Financial Instruments Tables Abstract
Summary of Changes in Convertible Debentures	A summary of changes in Convertible Debentures for the period ended December 31, 2020 was as follows: Balance at January 1, 2020 -- Issued during the year $ 335,101 Change in fair value recognized in operations $ 2,773 Balance at December 31, 2020 $ 305,684

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Income Taxes Tables Abstract
Schedule of Provision for Income Taxes	The provision (benefit) for income taxes consisted of the following for the period from conversion to December 31, 2020: 2020 Current $ 0 Deferred (111,000 ) Change in valuation allowance 111,000 Income tax provision (benefit) $ 0
Schedule of Effective Income Tax Rate Reconciliation	The following table reconciles the effective income tax rates with the statutory rates for the period from the conversion date to December 31, 2020: U.S. federal statutory rate 21.0 % State tax, net of federal benefit 5.0 % Change in valuation allowance 26.0 % Effective income tax rate — %
Schedule of Deferred Tax Assets	Deferred tax assets are comprised of the following: December 31, 2020 Net operating loss carryforwards $ 111,000 Valuation allowance (111,000 ) Net deferred tax assets $ 0

Shareholders Equity (Details)

Shareholders Equity (Details)	Dec. 31, 2020shares
Series A Preferred Stock - $.001 Par Value[Member]
Shares Authorized	156,937
Shares Outstanding	156,837
Undesignated Preferred Stock $.001 Par Value [Member]
Shares Authorized	1,843,163
Shares Outstanding	0
Common Stock - $.001 Par Value [Member]
Shares Authorized	200,000,000
Shares Outstanding	9,701,269

Derivative Financial Instrume_3

Derivative Financial Instruments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Change in fair value recognized in operations	$ 2,773
Balance at December 31, 2020	305,684
Derivative Financial Instruments, Liabilities [Member]
Balance at January 1, 2020
Issued during the year	335,101
Change in fair value recognized in operations	2,773
Balance at December 31, 2020	$ 305,684

Income Taxes (Schedule Of Provi

Income Taxes (Schedule Of Provision For Income Taxes) (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Income Taxes Schedule Of Provision For Income Taxes
Current	$ 0
Deferred	(111,000)
Change in valuation allowance	(111,000)
Income tax provision (benefit)	$ 0

Income Taxes (Schedule Of Effec

Income Taxes (Schedule Of Effective Income Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2020
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation
U.S. federal statutory rate	21.00%
State tax, net of federal benefit	5.00%
Change in Valuation allowance	(26.00%)
Effective income tax rate	0.00%

Income Taxes (Schedule Of Defer

Income Taxes (Schedule Of Deferred Tax Assets) (Details)	Dec. 31, 2020USD ($)
Income Taxes Schedule Of Deferred Tax Assets
Net operating loss carryforwards	$ 111,000
Valuation allowance	111,000
Net deferred tax assets	$ 0

Organization And Nature Of Bu_2

Organization And Nature Of Business (Narrative) (Details) - shares	Nov. 12, 2020	Dec. 31, 2020	Dec. 31, 2019
Series A preferred stock issued, shares		156,837	156,837
Series A Preferred Stock [Member]
Series A preferred stock issued, shares		156,837
Exchange Agreement With Medi-Scan, Inc [Member]
Agreement description	Healthtech Solutions, Inc. entered into an exchange agreement with Medi-Scan, Inc. ("Medi-Scan") and all of the shareholders of Medi-Scan, pursuant to which the shareholders of Medi-Scan agreed to transfer all of the issued and outstanding stock of Medi-Scan to Healthtech Solutions, Inc., and Healthtech Solutions, Inc. agreed to issue to the shareholders of Medi-Scan, Inc. 156,837 shares of its Series A Preferred Stock, representing 97% of the equity in Healthtech Solutions. The exchange of equity (the "Share Exchange") was completed on November 16, 2020.
Exchange Agreement With Medi-Scan, Inc [Member] | Series A Preferred Stock [Member] | Shareholders Of Medi-Scan, Inc [Member]
Series A preferred stock issued, shares	156,837

Related Parties (Narrative) (De

Related Parties (Narrative) (Details) - USD ($)	1 Months Ended	17 Months Ended	20 Months Ended
	May 31, 2020	May 31, 2020	Sep. 04, 2020
Related Party Transaction [Line Items]
Debt instrument description, related party	David Rubin, through his personal holding company, Storm Funding LLC, agreed to contribute $250,000 to Medi-Scan in exchange for a 25% equity interest in Medi-Scan. During the remainder of 2020, Mr. Rubin satisfied $245,442 of the obligation: he contributed $142,761 by paying obligations incurred by Medi-Scan in that amount, and Mr. Rubin satisfied a total of $102,681 of the obligation by contributing to Medi-Scan the services of administrative employees employed by eProdigy Financial LLC, a company owned by Mr. Rubin. The hourly market value of services performed by eProdigy employees for the benefit of Medi-Scan was credited to Mr. Rubin's capital account.
Board of Directors - Denis Kleinfeld [Member]
Related Party Transaction [Line Items]
Related party transaction description		During 2019 and the the first five months of 2020, Medi-Scan paid $10,000 per month to a law firm owned by Denis Kleinfeld, who was a managing member of Medi-Scan at that time and became a member of the Board of Directors of Healthtech Solutions in September 2020. The payment included $1,447 as compensation for use of the law firm's offices as the executive offices of Medi-Scan, the remainder was compensation for the administrative and other services of employees of the law firm, and for legal services by Mr. Kleinfeld.
Expenses paid by medi scan		$ 10,000
General & administrative - related party		$ 1,447
Sole Officer and Director, Secretary - Robert Brantl [Member]
Related Party Transaction [Line Items]
General & administrative - related party			$ 51,228

Shareholders Equity (Narrative)

Shareholders Equity (Narrative) (Details) - $ / shares	1 Months Ended	12 Months Ended		36 Months Ended
	May 31, 2020	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2020
Medi Scans Founder [Member]
Capital contribution description	Medi-Scan entered into agreement with Storm Funding LLC, a company owned by David Rubin. Storm Funding LLC committed to invest $250,000 in exchange for a 25% membership interest in Medi-Scan. At the same time, David Rubin joined Medi-Scan as Executive Chairman. As of December 31, 2020, $245,442 of the commitment had been invested into Medi-Scan.		The Richard F. Parker and Charlotte Parker Revocable Living Trust acquired a 25% membership interest in Medi-Scan in consideration of Richard F. Parker's contribution of intellectual property to Medi-Scan. The contribution was valued at $116,667, which was based on the capital contributions by the founding members of the Company.	Medi-Scan's founders contributed $25,000 during the year ended December 31, 2020, $374,000 during the year ending December 31, 2019 and $350,000 during the period ending December 31, 2018.
Series A Preferred Stock [Member]
Preferred share conversion term		Each share of Series A Preferred Stock is convertible by the holder into two thousand (2,000) shares of Common Stock.
Preferred stock voting rights		Each share of Series A Preferred Stock entitles a stockholder to voting rights equivalent to those of 2,000 shares of Common Stock on all matters upon which stockholders are permitted to vote.
Preferred stock liquidation preference		$ 0.01		$ 0.01

Exchangeable Notes And Conver_2

Exchangeable Notes And Convertible Debentures (Narrative) (Details) - USD ($)	Dec. 31, 2020	Nov. 30, 2020	May 31, 2020	Sep. 30, 2020	Aug. 31, 2020
Exchangeable promissory note description			David Rubin, through his personal holding company, Storm Funding LLC, agreed to contribute $250,000 to Medi-Scan in exchange for a 25% equity interest in Medi-Scan. During the remainder of 2020, Mr. Rubin satisfied $245,442 of the obligation: he contributed $142,761 by paying obligations incurred by Medi-Scan in that amount, and Mr. Rubin satisfied a total of $102,681 of the obligation by contributing to Medi-Scan the services of administrative employees employed by eProdigy Financial LLC, a company owned by Mr. Rubin. The hourly market value of services performed by eProdigy employees for the benefit of Medi-Scan was credited to Mr. Rubin's capital account.
7% Exchangeable Promissory Notes [Member]
Debt instrument principal amount		$ 381,505		$ 375,000	$ 375,000
Exchangeable promissory note description		By reason of the Share Exchange, the four 7% Exchangeable Promissory Notes were automatically exchanged for 7% Convertible Debentures issued by Healthtech Solutions in a principal amount of $381,505, which was equal to the principal of and accrued interest on the Notes. Then, during December of 2020, Healthtech Solutions issued four additional 7% Convertible Debentures in the aggregate principal amount of $250,000 in exchange for payment of cash in that amount.		Medi-Scan issued four 7% Exchangeable Promissory Notes in the aggregate principal amount of $375,000. Principal and interest were payable on the Notes on January 31, 2021. The Notes provided that, in the event that Medi-Scan was acquired by a corporation whose common stock was registered with the SEC, the Notes would be automatically exchanged for 7% convertible debentures issued by that acquirer.
7% Exchangeable Promissory Notes [Member] | Common Stock [Member]
Convertible debenture conversion term	The 7% Convertible Debentures are convertible into common stock, at the holders’ option, at a 30% discount to the market price of the Company’s common stock. The Company has determined that the conversion feature represents a derivative financial instrument embedded in the Debentures. The accounting treatment of derivative financial instruments requires that the Company record the fair value of that derivative financial instrument as a discount to the value of the Debentures as of the inception date of each Debenture.
Fair value of derivative liability discount	$ 335,101

Derivative Financial Instrume_4

Derivative Financial Instruments (Narrative) (Details) - Derivative Financial Instruments, Liabilities [Member]	12 Months Ended
	Dec. 31, 2020
Dividend yield	0.00%
Expected volatility	167.00%
Weighted average risk free interest rate	9.00%
Expected life	Jan. 31, 2024

Income Tax (Narrative) (Details

Income Tax (Narrative) (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Income Tax Narrative
Net operating loss carryforward	$ 427,000
Operating loss carryforward limitations on use	Will expire beginning in 2027. Through 2036, the amount and utilization of any future net operating loss carry-forwards may be subject to limitations set forth by the Internal Revenue Code.
Changes in Valuation allowance	$ 111,000